Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Denali Builds Neurodegeneration Pipeline Through Discovery, Collaborations And Lots Of Cash

Executive Summary

The amount of venture capital that Denali Therapeutics Inc. has raised and the number of collaborations it's negotiated in less than two years is pretty staggering for a startup biopharmaceutical company, not to mention a startup focused on the central nervous system and neurodegeneration.

Advertisement

Related Content

VC Roundup: Flagship’s New Fund Designed To Raise Its Stake In Startups
Biopharma Quarterly Dealmaking Statistics, Q3 2016
Start-Up Quarterly Statistics, Q3 2016
Tech Transfer Roundup: Voyager Brings Home Pair Of CNS Collaborations
Denali launches with ex-Genentech management and $217m-deep pockets

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097186

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel